• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·6986.TWO
Share

HeXun Biosciences Co., Ltd. Stocks

NT$ 54.3Last Updated 24.06.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

NT$ 82.80M

NT$ 54.3
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

HeXun Biosciences Co., Ltd., a Taiwanese enterprise, focuses on the research, development, and application of stem cell technologies and treatments. The company also offers a comprehensive suite of related services, including contract development and manufacturing for various cell types and their derivatives, outsourced production capabilities, quality control inspections, expert consulting, laboratory information management system (LIMS) implementation, and sterile (aseptic) filling solutions. Founded in 2019, its operations are headquartered in Taoyuan City, Taiwan.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

24.06.2026 13:03

Elon Musk Is No Longer a Trillionaire — Bloomberg

24.06.2026 11:37

Mag7 shares have experienced their biggest sell-off in over a year. What's next?

24.06.2026 10:35

Top Stories This Morning: Asia Recovers After Sell-Off, SpaceX Raises $25 Billion

24.06.2026 09:00

Apollo and Morgan Stanley have once again restricted withdrawals from private credit funds

24.06.2026 08:00

Alibaba has filed a lawsuit against the Pentagon over allegations of ties to the Chinese military

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026